We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MSGE:NYSEMadison Square Garden Entertainment Corp. Analysis

Data as of 2026-04-18 - not real-time

$62.78

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Madison Square Garden Entertainment is trading at $62.78, just below its 30‑day resistance of $63.14 and above the 20‑day SMA of $59.27, while the MACD shows a bullish divergence (line $0.86 above signal $0.48) and RSI sits at 63, indicating momentum but no extreme overbought condition. DCF analysis suggests a fair value of $71.08, implying roughly a 10% upside, and BTIG’s recent buy coverage with a median 12‑month price target of $69 reinforces the upside thesis. Fundamentally, revenue grew 13% YoY to $1.01 B with solid operating margins (35.7%) and a modest profit margin (5.1%), yet the balance sheet is heavily leveraged (debt‑to‑equity > 3,000%) and ROE is low at 2.2%, limiting upside from earnings growth alone. The stock carries no dividend, exhibits moderate 30‑day volatility (≈28%) and a beta near 0.9, placing it in a typical consumer‑cyclical risk profile, while liquidity remains adequate given a $3 B market cap and stable volume. Overall, the combination of technical strength, a DCF‑derived discount, and analyst support suggests a near‑term buying opportunity, but the high leverage and valuation multiples (PE ≈ 58, PB ≈ 82) warrant caution for long‑term investors.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and RSI indicating upward momentum
  • Price trading near support with limited downside to $54.30
  • Analyst buy rating and upside to DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 13% and strong operating margins
  • DCF fair value providing ~10% upside
  • Stable volume and adequate market cap supporting liquidity

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and low ROE limiting earnings sustainability
  • Elevated valuation multiples (PE, PB) relative to peers
  • Consumer‑cyclical exposure to economic cycles

Key Metrics & Analysis

Financial Health

Revenue Growth12.90%
Profit Margin5.12%
P/E Ratio57.6
ROE224.08%
ROA5.93%
Debt/Equity3319.62
P/B Ratio82.4
Op. Cash Flow$214.0M
Free Cash Flow$189.8M

Technical Analysis

TrendNeutral
RSI63.2
Support$54.30
Resistance$63.14
MA 20$59.27
MA 50$59.76
MA 200$49.85
MACDBullish
VolumeStable
Fear & Greed Index90.21

Valuation

Fair Value$71.08
Target Price$69.13
Upside/Downside10.11%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.92
Volatility28.43%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.